364 related articles for article (PubMed ID: 2374150)
1. 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
Sarges R; Howard HR; Browne RG; Lebel LA; Seymour PA; Koe BK
J Med Chem; 1990 Aug; 33(8):2240-54. PubMed ID: 2374150
[TBL] [Abstract][Full Text] [Related]
2. [1,2,4]Triazolo[4,3-a]quinoxalin-4-amines: a new class of A1 receptor selective adenosine antagonists.
Trivedi BK; Bruns RF
J Med Chem; 1988 May; 31(5):1011-4. PubMed ID: 3361571
[TBL] [Abstract][Full Text] [Related]
3. 7-Deaza-2-phenyladenines: structure-activity relationships of potent A1 selective adenosine receptor antagonists.
Müller CE; Hide I; Daly JW; Rothenhäusler K; Eger K
J Med Chem; 1990 Oct; 33(10):2822-8. PubMed ID: 2213835
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes.
Bruns RF; Lu GH; Pugsley TA
Mol Pharmacol; 1986 Apr; 29(4):331-46. PubMed ID: 3010074
[TBL] [Abstract][Full Text] [Related]
5. [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain.
Jarvis MF; Schulz R; Hutchison AJ; Do UH; Sills MA; Williams M
J Pharmacol Exp Ther; 1989 Dec; 251(3):888-93. PubMed ID: 2600819
[TBL] [Abstract][Full Text] [Related]
6. Effects of the new A2 adenosine receptor antagonist 8FB-PTP, an 8 substituted pyrazolo-triazolo-pyrimidine, on in vitro functional models.
Dionisotti S; Conti A; Sandoli D; Zocchi C; Gatta F; Ongini E
Br J Pharmacol; 1994 Jun; 112(2):659-65. PubMed ID: 8075885
[TBL] [Abstract][Full Text] [Related]
7. 1,2,4-Triazolo[1,5-a]quinoxaline derivatives: synthesis and biological evaluation as adenosine receptor antagonists.
Catarzi D; Colotta V; Varano F; Filacchioni G; Martini C; Trincavelli L; Lucacchini A
Farmaco; 2004 Feb; 59(2):71-81. PubMed ID: 14871498
[TBL] [Abstract][Full Text] [Related]
8. 8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.
Shimada J; Suzuki F; Nonaka H; Ishii A
J Med Chem; 1992 Mar; 35(5):924-30. PubMed ID: 1548682
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.
Colotta V; Catarzi D; Varano F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Traini C; Pugliese AM; Pedata F; Morizzo E; Moro S
Bioorg Med Chem; 2008 Jun; 16(11):6086-102. PubMed ID: 18468446
[TBL] [Abstract][Full Text] [Related]
10. 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists.
van Galen PJ; Nissen P; van Wijngaarden I; IJzerman AP; Soudijn W
J Med Chem; 1991 Mar; 34(3):1202-6. PubMed ID: 2002461
[TBL] [Abstract][Full Text] [Related]
11. N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor.
Thompson RD; Secunda S; Daly JW; Olsson RA
J Med Chem; 1991 Sep; 34(9):2877-82. PubMed ID: 1895305
[TBL] [Abstract][Full Text] [Related]
12. 1-substituted 4-[chloropyrazolyl][1,2,4]triazolo[4,3-a]quinoxalines: synthesis and structure-activity relationships of a new class of benzodiazepine and adenosine receptor ligands.
Matuszczak B; Pekala E; Müller CE
Arch Pharm (Weinheim); 1998 May; 331(5):163-9. PubMed ID: 9691247
[TBL] [Abstract][Full Text] [Related]
13. Excitatory transmitter amino acid release from the ischemic rat cerebral cortex: effects of adenosine receptor agonists and antagonists.
Simpson RE; O'Regan MH; Perkins LM; Phillis JW
J Neurochem; 1992 May; 58(5):1683-90. PubMed ID: 1348522
[TBL] [Abstract][Full Text] [Related]
14. N6-substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors.
Olsson RA; Kusachi S; Thompson RD; Ukena D; Padgett W; Daly JW
J Med Chem; 1986 Sep; 29(9):1683-9. PubMed ID: 3018244
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationships of 4-cycloalkylamino-1, 2, 4-triazolo[4, 3-a]quinoxalin-1- one derivatives as A1 and A3 adenosine receptor antagonists.
Colotta V; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Lucacchini A; Colotta V
Arch Pharm (Weinheim); 2004 Jan; 337(1):35-41. PubMed ID: 14760626
[TBL] [Abstract][Full Text] [Related]
16. Novel 3-aralkyl-7-(amino-substituted)-1,2,3-triazolo[4,5-d]pyrimidines with high affinity toward A1 adenosine receptors.
Betti L; Biagi G; Giannaccini G; Giorgi I; Livi O; Lucacchini A; Manera C; Scartoni V
J Med Chem; 1998 Feb; 41(5):668-73. PubMed ID: 9513594
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the binding of a novel nonxanthine adenosine antagonist radioligand, [3H]CGS 15943, to multiple affinity states of the adenosine A1 receptor in the rat cortex.
Jarvis MF; Williams M; Do UH; Sills MA
Mol Pharmacol; 1991 Jan; 39(1):49-54. PubMed ID: 1987452
[TBL] [Abstract][Full Text] [Related]
18. Repeated treatment with adenosine A1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene.
De Sarro G; Donato Di Paola E; Falconi U; Ferreri G; De Sarro A
Eur J Pharmacol; 1996 Dec; 317(2-3):239-45. PubMed ID: 8997606
[TBL] [Abstract][Full Text] [Related]
19. Trifunctional agents as a design strategy for tailoring ligand properties: irreversible inhibitors of A1 adenosine receptors.
Boring DL; Ji XD; Zimmet J; Taylor KE; Stiles GL; Jacobson KA
Bioconjug Chem; 1991; 2(2):77-88. PubMed ID: 1868116
[TBL] [Abstract][Full Text] [Related]
20. N6-phenyladenosines: pronounced effect of phenyl substituents on affinity for A2 adenosine receptors.
Kwatra MM; Leung E; Hosey MM; Green RD
J Med Chem; 1987 May; 30(5):954-6. PubMed ID: 3572985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
